Roots Analysis

done a detailed study on Antibody Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights • Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based products. • The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of antibody CMOs claim to operate as one stop shops and have presence across different regions. • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to antibodies for use across a number of different disease indications. • At present, the installed, global antibody contract manufacturing capacity is estimated to be approximately 2.2 million liters, distributed across companies of all sizes worldwide. • In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities. • In fact, ongoing capability improvement efforts and facility upgrades have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives in this domain. • Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade. • Antibody-based product developers are likely to continue to outsource their manufacturing operations in mid to long term, resulting in a multi-billion growth opportunity for contract service providers. Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Concept of an Antibody 3.3. Structure of an Antibody 3.4. Antibody Isotypes 3.5. Mechanism of Action of Antibodies 3.6. Types of Antibodies 3.6.1. Monoclonal Antibodies 3.6.2. Bispecific Antibodies 3.6.3. Polyclonal Antibodies 3.7. Overview of Contract Manufacturing 3.8. Need for Outsourcing in the Biopharmaceutical Industry 3.9. Advantages of Outsourcing Manufacturing Services 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Antibody Contract Manufacturers: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Number of Employees 4.2.3. Analysis by Scale of Operation 4.2.4. Analysis by Location of Headquarters 4.2.5. Analysis by Location of Antibody Manufacturing Facilities 4.2.6. Analysis by Type of Antibodies Manufactured 4.2.7. Analysis by Expression Systems Used 4.2.8. Analysis by Regulatory Accreditations / Certifications 4.2.9. Additional Services Offered 5. COMPANY COMPETITIVE ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Input Parameters 5.3. Methodology 5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America 5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe 5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia 6. COMPANY PROFILES 6.1. Chapter Overview 6.2. AGC Biologics 6.2.1. Company Overview 6.2.2. Service Portfolio 6.2.3. Manufacturing Facilities and Capabilities 6.2.4. Future Outlook 6.3. Aldevron 6.3.1. Company Overview 6.3.2. Service Portfolio 6.3.3. Manufacturing Facilities and Capabilities 6.3.4. Future Outlook 6.4. AMRI 6.4.1. Company Overview 6.4.2. Service Portfolio 6.4.3. Manufacturing Facilities and Capabilities 6.4.4. Future Outlook 6.5. BioXcellence (Boehringer Ingelheim) 6.5.1. Company Overview 6.5.2. Service Portfolio 6.5.3. Manufacturing Facilities and Capabilities 6.5.4. Future Outlook 6.6. Emergent BioSolutions 6.6.1. Company Overview 6.6.2. Service Portfolio 6.6.3. Manufacturing Facilities and Capabilities 6.6.4. Future Outlook 6.7. Eurofins CDMO 6.7.1. Company Overview 6.7.2. Service Portfolio 6.7.3. Manufacturing Facilities and Capabilities 6.7.4. Future Outlook 6.8. FUJIFILM Diosynth Biotechnologies 6.8.1. Company Overview 6.8.2. Service Portfolio 6.8.3. Manufacturing Facilities and Capabilities 6.8.4. Future Outlook 6.9. KBI Biopharma 6.9.1. Company Overview 6.9.2. Service Portfolio 6.9.3. Manufacturing Facilities and Capabilities 6.9.4. Future Outlook 6.10. Lonza 6.10.1. Company Overview 6.10.2. Service Portfolio 6.10.3. Manufacturing Facilities and Capabilities 6.10.4. Future Outlook 6.11. Nitto Avecia Pharma Services 6.11.1. Company Overview 6.11.2. Service Portfolio 6.11.3. Manufacturing Facilities and Capabilities 6.11.4. Future Outlook 6.12. Novasep 6.12.1. Company Overview 6.12.2. Service Portfolio 6.12.3. Manufacturing Facilities and Capabilities 6.12.4. Future Outlook 6.13. Pierre Fabre 6.13.1. Company Overview 6.13.2. Service Portfolio 6.13.3. Manufacturing Facilities and Capabilities 6.13.4. Future Outlook 6.14. Samsung BioLogics 6.14.1. Company Overview 6.14.2. Service Portfolio 6.14.3. Manufacturing Facilities and Capabilities 6.14.4. Future Outlook 6.15. Synthon 6.15.1. Company Overview 6.15.2. Service Portfolio 6.15.3. Manufacturing Facilities and Capabilities 6.15.4. Future Outlook 6.16. Thermo Fisher Scientific 6.16.1. Company Overview 6.16.2. Service Portfolio 6.16.3. Manufacturing Facilities and Capabilities 6.16.4. Future Outlook 7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES 7.1. Chapter Overview 7.2. Small Molecule Drugs and Biologics 7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics 7.2.2. Comparison of Key Specifications 7.2.3. Comparison of Manufacturing Processes 7.2.4. Comparison of Key Manufacturing related Challenges 8. BENCHMARK ANALYSIS 8.1. Chapter Overview 8.2. Methodology 8.3. Region-wise Benchmarking 8.3.1. North America, Peer Group I 8.3.2. North America, Peer Group II 8.3.3. North America, Peer Group III 8.3.4. Europe, Peer Group IV 8.3.5. Europe, Peer Group V 8.3.6. Europe, Peer Group VI 8.3.7. Asia, Peer Group VII 8.3.8. Asia, Peer Group VIII 8.4. Concluding Remarks 9. PARTNERSHIPS 9.1. Chapter Overview 9.2. Partnerships Models 9.3. Antibody Contract Manufacturing: List of Partnerships 9.3.1. Analysis by Year of Partnership 9.3.2. Analysis by Type of Partnership 9.3.3. Analysis by Year and Type of Partnership 9.3.4. Analysis by Type of Antibody 9.3.5. Analysis by Project Scale 9.3.6. Analysis by Focus Therapeutic Area 9.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership 9.3.8. Geographical Analysis 9.3.8.1. Continent-wise Distribution 9.3.8.2. Country-wise Distribution 10. RECENT EXPANSIONS 10.1. Chapter Overview 10.2. Antibody Contract Manufacturers: List of Expansions 10.2.1. Analysis by Year of Expansion 10.2.2. Analysis by Type of Expansion 10.2.3. Analysis by Type of Antibody 10.2.4. Analysis by Location of Manufacturing Facility 10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion 10.2.6. Analysis of Most Active Players by Number of Expansions 10.2.7. Geographical Analysis 10.2.7.1. Country-wise Distribution 11. CAPACITY ANALYSIS 11.1. Chapter Overview 11.2. Assumptions and Methodology 11.3. Antibody Contract Manufacturing: Installed Global Capacity 11.3.1. Analysis by Company Size 11.3.2. Analysis by Scale of Operation 11.3.3. Analysis by Expression System 11.3.4. Analysis by Location of Manufacturing Facility 11.3.5. Analysis by Geography and Scale of Operation 11.3.6. Analysis by Geography and Company Size 11.4. Concluding Remarks 12. DEMAND ANALYSIS 12.1 Chapter Overview 12.2 Assumptions and Methodology 12.3 Antibody Contract Manufacturing Market: Overall Annual Demand 12.3.1. Analysis by Scale of Operation 12.3.2. Analysis by Geography 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Assumptions and Forecast Methodology 13.3. Overall Antibody Contract Manufacturing Market, 2020-2030 13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody 13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size 13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation 13.7. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used 13.8. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography 13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030 13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies 13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies 13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies 13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations 13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations 13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations 13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell- based Operations 13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030 13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies 13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies 13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies 13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations 13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations 13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell- based Operations 13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations 13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030 13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies 13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies 13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies 13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations 13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations 13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations 13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations 14. SWOT ANALYSIS 14.1. Chapter Overview 14.2. Strengths 14.3. Weaknesses 14.4. Opportunities 14.5. Threats 14.6. Comparison of SWOT Factors 14.7. Concluding Remarks 15. FUTURE OF THE ANTIBODY CMO MARKET 15.1. Chapter Overview 15.2. Outsourcing Activity Anticipated to Witness Significant Growth 15.3. Shift from One-time Contractual Engagements to Strategic Partnerships 15.4. Adoption of New and Innovative Technologies 15.5. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment 15.6. Capability and Expertise Expansions by CMOs to become One Stop Shops 15.7. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities 15.8. Challenges Faced by both Sponsors and Service Providers 15.9. Concluding Remarks 16. INTERVIEW TRANSCRIPTS 16.1. Chapter Overview 16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific 16.3. David C Cunningham, Director Corporate Development, Goodwin Biotechnology 16.4. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences 17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS 18. APPENDIX 2: TABULATED DATA 19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com